Received:
Thursday, April 16, 2015
Commodity:
Recombinant Factor VIII Products
Investigation Number:
337-TA-956
Filed By:
Tom M. Schaumberg
Firm/Organization:
Adduci, Mastriani, & Schaumberg LLP
Behalf Of:
Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA.
Confidential:
Yes
Country:
None
Description:
Letter to Lisa R. Barton, Secretary, USITC; requesting that the Commission conduct an investigation under section 337 of the Tariff Act of 1930, as amended, regarding Certain Recombinant Factor VIII Products. The proposed respondents are Novo Nordisk A/S, Denmark and Novo Nordisk Inc., Plainsboro, New Jersey.
An official website of the United States government.